Trogenix raised €80m in Series A led by IQ Capital, joined by 4Bio, Cancer Research Horizons, Brain Tumour Fund, Eli Lilly, Meltwind, LongeVC and Calculus
01 October 2025
01 October 2025
Total investments received (USD): 112.83M
Round value (USD): 93.84M
Company: Trogenix
Related deals
NRG Therapeutics closed a £50 million Series B funding round w/ British Business Bank, SV Health, M Ventures, Novartis, Criteria Bio Ventures, Omega Funds
Investments
01 September 2025
Charm Therapeutics raised $80M Series B round co-led by New Enterprise Associates and SR One, w/ OrbiMed, F-Prime Capital, Khosla Ventures, and NVIDIA
Investments
02 August 2025
Ultromics raised $55 million through in a Series C round co-led by L&G, Allegis Capital, and Lightrock.
Investments
21 July 2025
Juvenescence raised $76m in a first close of its Series B1 round led by M42.
Investments
10 May 2025
Belgium
Austria
Germany
Denmark
Estonia
Finland
Iceland
Lithuania
Norway
Sweden
France
Ireland
Italy
Portugal